Introduction
Moraxella catarrhalis, once considered a non-pathogenic Neisseria that colonised the upper respiratory tract, is now recognised world-wide as a common pathogen, particularly in bronchitis (Nicotra et al., 1986; Wallace & Musher, 1986; Berk, 1990; Catlin, 1990) . Evidence to support its pathogenicity has come from several different areas of clinical study: firstly, occasional reports of bloodstream infection, such as bacteraemic pneumonia (Wallace & Oldfield, 1990) ; secondly, isolation of the bacterium in pure culture from tympanocentesis (Van Hare et al., 1987) , transtracheal aspiration (McLeod et al., 1983; Hager et al., 1987) and maxillary sinus aspirates (Wald et al., 1981) ; thirdly, measurement of specific antibody production or increased concentrations of antibodies in convalescent versus acute sera from symptomatic patients (Chapman et al., 1987; Chi et al., 1990) ; and fourthly, improvement of clinical symptoms with appropriate antibiotic therapy in symptomatic patients with respiratory infection and a heavy growth of M. catarrhalis from expectorated sputum (Chi et al., 1990) .
This international study on the susceptibility of M. catarrhalis to commonly used antibiotics was considered of particular interest because of the recent, rapid evolution of /Mactamase production by the organism. Initial reports of /Mactamase producing M. catarrhalis strains came from several European sites in 1977, but soon the phenomenon was being reported throughout the world (Malmvall, Brorsson & Johnson, 1977; Percival et al., 1977; Phillippon et al., 1986; Wallace, Nash & Steingrube, 1990) . By the mid-1980s between 70% and 90% of M. catarrhalis strains were reported to be /Mactamase producers (Alvarez et al., 1985) . The /Mactamases which confer resistance to amoxycillin and penicillin, have been characterised as BRO-1 and BRO-2 , and are strongly membrane associated. The prevalence of tetracycline and erythromycin resistance was also of interest to the international study group. Tetracycline resistance was first reported in 1983 among isolates in Sweden (Kallings et al., 1983; Kallings, 1986) . Prevalences of resistance to tetracycline of 15% in the Netherlands (Davies & Maesen, 1988) and 43% in China (Zheng & Cao, 1988) were reported by 1988. At about the same time, tetracycline resistance was reported in the USA . Erythromycin resistance was also first noted in Sweden in 1983 (Kallings et al., 1983) . Subsequent studies in the USA observed the emergence of strains with reduced susceptibility to erythromycin .
While second-and third-generation cephalosporin resistance has been uncommon in M. catarrhalis, increased MICs have been noted in recent years (Kallings, 1986; Davies & Maesen, 1988) ; the extent of cephalosporin resistance was therefore of particular interest to the study group.
Methods

Collection and identification of isolates
Fifteen centres participated in the study from March 1992 until December 1993. There were two centres in each of the UK, Spain, Germany, Italy and France, and five centres in the USA. Each centre identified isolates from patients with community-acquired lower respiratory tract infections. Specimens were collected within 48 h of admission. Isolates were preserved and sent in batches to the central reference laboratory (Felmingham et al., 1996) , where the identification of each strain was reconfirmed.
Susceptibility testing
MIC of 15 antibiotics were determined using a Sensititre microbroth dilution method with Mueller-Hinton broth. A final inoculum of 10 3 cfu/mL was used, and plates were incubated in air for 18 h. /?-Lactamase production was determined using the cefinase disc method (Felmingham et al., 1996) .
Data analysis
MICs were determined for each study antimicrobial agent. MIC breakpoints (Table I) were used to delineate sensitive, intermediate and resistant isolates. MICs were compared using MICso, MIC90 and the geometric mean (MICGM, the antilog of the mean log MIC). Differences in MICOM between centres in Europe and the USA were assessed by Student's r-test. Likewise, Student's Mest was used to compare the MICGM of /3-lactamase producing isolates with the MICOM of non-/?-lactamase producing isolates. The percentages of /Mactamase producing isolates in Europe and the USA were compared using the x 2 test (Table II) . Differences in the distribution of susceptible 
Results
Eight hundred and eighteen isolates of M. catarrhalis were obtained from the 15 participating centres. There were 587 and 231 isolates from European and USA centres, respectively (Table I) . M. catarrhalis was the third most commonly isolated pathogen in the study after Streptococcus pneumoniae (1731 isolates) and Haemophilus influenzae (1368 isolates). M. catarrhalis represented 13.5% of all European isolates and 13.5% of all USA isolates (Felmingham et al.. 1996) .
Of the 818 M. catarrhalis isolates. 668 (81 7%) were /Mactamase producers. There was a significantly higher prevalence of /7-lactamase production in isolates from the USA (92.2%) compared with those from Europe (77.5%, P< 0.001). By 1993 the proportion of /Mactamase producers amongst the European isolates had increased significantly to 81.6% (P < 0.001). with a smaller, non-significant increase in the USA 
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(93.8%). Over the 2 year study period the prevalence of /Mactamase production varied between individual centres from 70% (87 of 119 strains) to 100% (16 of 16). Table II summarises the data on the distribution of /Mactamase producing M. catarrhalis. Table I 
Penicillin and amoxycillin
Using an MIC breakpoint of 0.25 mg/L, penicillin resistance was present in 679 of 818 isolates (83.0%). Resistance was more prevalent in US isolates (92.2%) than in European isolates (79.4%, P< 0.001). In addition, the MICGM of US isolates (3.57 mg/L) was significantly higher than the MICGM of European isolates (1.26 mg/L). (Table IV) . The USA MIC* of 8.0 mg/L was also higher than the European MIC*, of 2.0 mg/L (Table III ). All 0-lactamase producing M. catarrhalis had MICs 5*0.25 mg/L but, for these strains, the USA MICGM of 5.25 mg/L was significantly higher than the corresponding European MIC GM of 3.36 mg/L (Table IV) . Among /Mactamase-negative M. catarrhalis, 11 of 132 European isolates were penicillin resistant (8.3%), while 18 of 18 USA isolates had MICs ^ 0.06 mg/L (penicillin sensitive). Amoxycillin resistance was observed in 457 of 818 (55.9%) study isolates. As expected, resistance to amoxycillin was more prevalent in the USA, where 73% (169 of 231) of the isolates were amoxycillin resistant compared with 49% (288 of 587) of the European isolates (P < 0.001). As shown in Table IV , the USA MICGM of 0.98 mg/L was significantly higher than the European MICGM of 0.44 mg/L. In Europe /Mactamase-negative isolates had MICs of amoxycillin which ranged from 0.06-1.0 mg/L. Five of 135 strains were resistant to amoxycillin (MIC ^ 0.5 mg/L). All 15 /Mactamase-negative strains in the USA had an MIC of 0.06 mg/L.
All isolates of M. catarrhalis from Europe and the USA were susceptible to amoxycillin/clavulanate (Table I ). The MIGw was very low (0.12 mg/L, Table III ). The distribution of MICs of amoxycillin was, as expected, much wider than that for amoxycillin/clavulanate.
Macrolides
No isolate of M. catarrhalis was resistant to erythromycin, although eight strains did show intermediate susceptibility to erythromycin (MIC >0.5 mg/L, Table I ). European and USA MICo M s (Table IV) and MIQoS were similar (Table III) . MICs ^0.5 mg/L were determined in 19 isolates, and 15 of these were from European centres.
All USA strains of M. catarrhalis were markedly susceptible to clarithromycin (range 0.06-0.5 mg/L) and azithromycin (range 0.06-0.5 mg/L), whilst in Europe some strains had MICs of these antibiotics >0.5 mg/L (Table I ). The MICsoS (Table III) and MICGMS (Table IV) are similar for European and USA isolates. There were no differences between 1992 and 1993 in MIC frequency distributions of any of the macrolides tested ( Figure) .
Cephalosporins
All but three isolates were sensitive to the four cephalosporins tested. Two isolates showed intermediate sensitivity to cefaclor (MIC 16 mg/L); one each in Europe and the USA. Both were isolated in 1993 and both were /Mactamase producers. One (Table IV) , although there were no statistically significant differences observed between European and USA centres for /f-lactamase-negative strains. For all cephalosporins the MICGM of all isolates from the USA was significantly higher than the MICGM of all isolates from Europe; however, this is largely a reflection of the higher prevalence of /Mactamase producing strains in the USA (Table IV) . Cefuroxime, cefixime and ceftriaxone each had similar MIC frequency distributions in 1992 and 1993 (Figure) . Cefaclor MICs differed slightly, with MIC»s and MIQoS of 0.5 and 1 mg/L in 1992 and 1 and 2 mg/L in 1993. These values were also obtained with /Mactamase-producing strains, whilst non-/Mactamase-producing strains yielded an MICM ^0.25 mg/L in both 1992 and 1993.
Quinolones
All isolates from study centres in Europe and the USA were ciprofloxacin sensitive ( Table I ). The MIC ranges for European and USA isolates were similar, as were the MIC50S (Table III) and MICGM, (Table IV) . All but one isolate were sensitive to ofloxacin. One isolate from the USA had intermediate sensitivity (MIC 4 mg/L). Ofloxacin MIC50S for 1992 and 1993 were 0.12 and 0.06 mg/L, respectively. Over the same period MIC«s remained constant (0.12 mg/L), as did both MIC50S and MIG»s for ciprofloxacin (0.03 and 0.06 mg/L).
Other antibiotics
All strains examined were highly susceptible to doxycycline (Table I) . Four isolates had MICs >0.5 mg/L and these were from European centres. Similarly, all M. catarrhalis strains were sensitive to co-trimoxazole (Table I) . Twenty-two isolates had MICs > 1.0 mg/L, 19 of which were from European centres (3.2%) and three from the USA (1.3%; no statistically significant difference). MIC50S and MICGMI for doxycycline and co-trimoxazole were similar (Table III and Table IV) .
Discussion
As M. catarrhalis has gained recognition as a pathogen over the past decade it also has shown an increased prevalence of /Mactamase production. screened stored isolates from CDC (USA) and found no /Mactamase-producing strains between 1952 and 1976 (Zheng, 1988) . Oberhoeffer & Towle (1982) reported that 40% of strains produced /Mactamase in the late 1970s. Our own group (Alvarez et al., 1985) and others (Shurin et al., 1983; Winstanley & Spencer, 1986) reported corresponding prevalences of 80% in the early 1980s. Jorgenson et al. (1989) , in the most recent multicentre study in the USA, found that 83% of the isolates were /Mactamase producers. Several studies have documented the rising incidence of /Mactamase production and penicillin resistance in Europe. By the mid-1980s the prevalence of 0-lactamase production in the UK was 35-70% (McLeod et al., 1986; Winstanley & Spencer, 1986) . More recently 80% (Riley, Digiovanni & Hoyne, 1987) and 90% (Powell et al., 1991; Fung et al., 1992) of UK isolates were 0-lactamase producers. The present multicentre international study confirms the high and increasing prevalence of /Mactamase production on both continents. The 100% incidence of /Mactamase production at some USA centres is the inevitable endpoint of a trend of increasing prevalence. The study also confirms that many /Mactamase-positive organisms remain susceptible to amoxycillin, although it is the general recommendation that amoxycillin should not be used for /Mactamase producing strains of M. catarrhalis. Amoxycillinsensitive /J-lactamase-producing M. catarrhalis are likely to be BRO-2 producers. In one study production of BRO-2 enzymes increased the MIC of amoxycillin four-fold, whereas BRO-1 producers had a 25-fold higher MIC of amoxycillin (Kallings, 1986) .
The relatively high MICs of amoxycillin for /Mactamase-negative M. catarrhalis, particularly noted in European centres, suggest a further developing mechanism of resistance which requires additional study. This relative resistance may reflect changes in penicillin-binding proteins, as has been noted in S. pneumoniae and H. influenzae, or changes in permeability (Hackenbeck, Tarpay & Tomasz, 1980; Quinn, 1989) .
Our study, as previous studies, has found only a modest effect of /Mactamase production on the in-vitro susceptibility of M. catarrhalis to oral or parenteral cephalosporins. Previous studies (Kallings et al., 1983; Ahmad et al., 1984; Doern & TutxJrt, 1988) found two-to four-fold MIC increases among /Mactamase producers. We also found only a two-fold difference in MICs of cefaclor, cefuroxime and ceftriaxone for /Mactamase producers versus non-producers (Table IV) . There was a smaller difference in MICs of cefixime for /Mactamase producers versus non-producers (Table IV) . In general, oral cephalosporins have been found to be almost, but not completely stable with respect to the /Mactamases produced by M. catarrhalis. Fung, Yeo & Livermore (1994) recently studied 413 isolates from the UK. MICs of all cephalosporins were low for /Mactamase producers. BRO-2 enzyme producers had a 1.5-5-fold higher mean MIC. BRO-1 producers had an even smaller effect. Ikeda et al. (1993) in Japan performed in-vitro studies of BRO-1 and BRO-2 on antibiotic hydrolysis. Both enzymes hydrolyzed cefaclor as rapidly as penicillin and amoxycillin, but cefixime was a poor substrate. A trend in cefaclor resistance may be developing as intermediate susceptibility has been observed in this international study and in other centres. Stefani et al. (1992) in Italy found that 4% of M. catarrhalis isolates were resistant to cefaclor and 10% were intermediately susceptible. All strains were sensitive to ceftriaxone, ceftazidime and cefotaxime. We also found uniform susceptibility to ceftriaxone. Nash et al. (1991) , found that M. catarrhalis BRO-2 producers had no impact on the MICs of cefixime, cefuroxime, cephalexin or cefaclor. BRO-1 producers did exhibit a two-to four-fold increase in MIC. Our study did not distinguish BRO-1 from BRO-2 enzymes. However, it appears that the MICs of cephalosporins for M. catarrhalis are variable and although /Mactamase production does confer some protection against these antibiotics, this factor alone cannot explain all the data.
While M. catarrhalis resistance to erythromycin was reported as early as 1983 and has been confirmed from the Netherlands, New Zealand and the USA, any increasing prevalence of erythromycin-resistant strains is difficult to find. Powell et al. (1991) , reported a 3% incidence of erythromycin resistance from the UK in 1991, but recent reports from Nash et al. (1991) in the USA, Forsgren & Walder (1994) in Sweden, Stefani et al. (1992) in Italy, and Struelens et al. (1991) in Belgium, have found no erythromycin resistance among their isolates. Our study did find a few strains that were relatively resistant to erythromycin in European centres but not in the USA centres. This may be explained by the higher use of erythromycin and easier availability of the drug in some European countries (Geslin, Fremaux & Sissia, 1993) . With the increased use of newer macrolides in the USA this difference may be short-lived. As expected, a high level of susceptibility to the newer macrolides, clarithromycin and azithromycin, was apparent both in the USA and Europe.
No doxycycline-resistant strains were noted in this study. The tetB resistance determinant has been identified in two resistant strains of M. catarrhalis by , and transfer of this determinant in vitro has been difficult. This may explain the slow spread of tetracycline resistance in large scale longitudinal studies.
M. catarrhalis isolates are uniformly resistant to trimethoprim which has been a useful antibiotic in the development of selective media for the organism. However, co-trimoxazole often used in the USA for tracheobronchitis, has generally shown good activity against the organism with MIGwS of 0.5 mg/L. Sporadic resistance has occurred and relatively resistant strains were identified in this study both in the USA and Europe. In the authors' centre, we have observed a trend toward higher MICs of co-trimoxazole over the past 15 years. This will be an important antibiotic to study for the development of resistance in the future.
